Saturday 17 October 2026
Export BDSX’s income statement to Excel — free account
Biodesix, Inc.
BDSX Healthcare Diagnostics & Research
Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024. In the quarter to June 2026, revenue grew 34.2%, EPS grew 55.6%, free cash flow grew 72.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
23.66
1.05
−4.25%
Follow BDSX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.26 | 1.46 | 0.58 | 0.71 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(148.64) | (13.77) | 66.00 | (6.38) | |
P/B ratio |
25.39 | 15.33 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.42 | 1.67 | 0.90 | 1.09 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(12.56) | (6.48) | (3.43) | (3.10) | |
EV/FCF |
(12.21) | (6.37) | (3.37) | (2.97) | |
Quick Ratio |
2.56 | 2.42 | 1.61 | 1.61 | |
Current Ratio |
2.85 | 2.82 | 1.87 | 1.84 | |
Net Debt/EBITDA |
(4.63) | (4.70) | (125.39) | (5.72) | |
Debt/Assets |
49.11% | 49.12% | 54.24% | 53.11% | |
Debt/Equity |
5.12 | 5.09 | (19.25) | (27.36) | |
Asset Turnover |
1.12 | 1.06 | 0.96 | 0.84 | |
Operating CF/Net income |
0.21 | 1.30 | (0.20) | 1.02 | |
Capex/Depreciation |
(0.14) | (0.08) | (0.06) | (0.04) | |
Interest Coverage |
(2.72) | (3.14) | (0.96) | (3.40) | |
Research and Development Expense of Revenue |
11.67% | 12.85% | 9.98% | 13.74% | |
Selling, General and Administrative Expense of Revenue |
90.40% | 94.94% | 79.89% | 99.75% | |
Intangible Assets out of Total Assets |
0.19 | 0.20 | 0.22 | 0.22 | |
Share Based Compensation of Revenue |
3.05% | 4.36% | 3.74% | 4.84% | |
Graham Net Nets |
(0.18) | (0.32) | (1.12) | (1.01) | |
Graham Number |
0.00 | 0.00 | 5.97 | 5.36 | |
Earnings Yield |
(14.06%) | (28.00%) | (71.32%) | (73.64%) | |
Free Cash Flow Yield |
(8.79%) | (18.03%) | (46.11%) | (51.79%) | |
Revenue per Share |
2.61 | 2.65 | 3.81 | 2.90 | |
Operating CF per Share |
(0.15) | (1.05) | 0.10 | (1.18) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.18) | (1.07) | 0.09 | (1.19) | |
Cash per Share |
2.91 | 2.65 | 2.51 | 2.21 | |
Shareholders Equity per Share |
0.89 | 0.95 | (0.33) | (0.23) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.89 | 0.95 | (0.33) | (0.23) | |
Free Cash Flow |
(1.82) | (10.31) | 0.67 | (8.95) | |
Working Capital |
28.27 | 26.42 | 15.08 | 15.25 | |
Capital Expenditures |
(0.25) | (0.14) | (0.10) | (0.07) | |
Net Current Asset Value |
(42.62) | (44.59) | (57.42) | (57.04) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
8.28 | 8.57 | 8.82 | 10.36 | |
Average Payables |
2.57 | 3.29 | 2.64 | 3.08 | |
Average Assets |
91.53 | 90.44 | 92.36 | 95.73 | |
Average Common Equity |
5.14 | 10.10 | 9.21 | 13.07 |
Columns are period end dates